alexa Oral CF101 in Patients with Rheumatoid Arthritis

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Oral CF101 in Patients with Rheumatoid Arthritis

omicsonline.org/open-access/therapeutic-effect-of-oral-cf101-in-patients-with-rheumatoid-arthritis-a-randomized-doubleblind-placebocontrolled-phase-ii-study-1745-7580-1000087.pdf

The prognosis and management of Rheumatoid Arthritis (RA) has improved dramatically due to the introduction of new therapies and early treatment. The widely used anti-TNF agents are costly, exhibit a high rate of side effects and approximately 30-40% of patients fail to respond to those agents. In principle, treatments for RA are applied by trial and error, according to drug response, and adverse event experience. Hence, the approach for developing new modes of treatment in RA should be to identify patients who are more likely to respond to specific therapies in a safe and effective manner, i.e., personalized therapy. Currently, research is focused on the development of novel biologic therapies and small molecule drugs that will meet those requirements. For more information regarding thi sarticle, kindly go through the above link.

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords